![](https://www2.mrc-lmb.cam.ac.uk/wordpress/wp-content/uploads/HumiraVectibix-150x150.jpg)
Two therapies with their roots in antibody technology developed in the LMB and the Scripps Research Institute* have recently emerged as promising new drug candidates to treat lupus, a potentially fatal autoimmune disease, and anthrax, a pressing concern due to bioterrorism.